When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ARCT - Arcturus: Potential Based On Rare Disease Therapy ARCT-810
Arcturus Therapeutics Ltd.
An EUA for ARCT-154 as a COVID-19 vaccine in Vietnam has been submitted, with expected approval in 2022.
A phase 2 study using ARCT-810 as a treatment option for patients with OTC deficiency is expected to start in mid-2022; results are then expected 2nd half of 2022.
A CTA to begin a study using ARCT-032 for the treatment of patients with Cystic Fibrosis is expected Q3 of 2022.
Arcturus had $319.7 million in cash as of March 31, 2022; enough cash to fund operations into late 2023.